Search results
Xyphos and Poseida to develop allogeneic cell therapies for cancer
Pharmaceutical Technology via Yahoo Finance· 2 hours agoPoseida focuses on progressing cell and gene therapies that have the potential to cure certain...
New technique improves T cell-based immunotherapies for solid tumors
Medical Xpress· 17 hours agoScientists from Scripps Research have enhanced an existing immunotherapy by removing the sugar coating surrounding solid tumors—such as in melanoma, breast, and prostate cancer—so T ...
Replay wins IND clearance for PRAME T cell cancer therapy
Pharmaceutical Technology via Yahoo Finance· 21 hours agoGenome writing company Replay Bio has had its investigational new drug (IND) application cleared by...
Astellas and Poseida join forces for cancer cell therapy By Investing.com
Investing.com· 11 hours ago(TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have entered a research collaboration and...
Revolutionizing Cancer Treatment: Key to Prolonging CAR T Cell Life Uncovered
SciTechDaily· 2 days agoFOXO1 is required for T cell memory and is linked to longer-lasting clinical outcomes in CAR T cell ...
... Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic...
FOX 4 Kansas City· 11 hours agoPoseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
Cell and gene therapy companies trip at scalability hurdle
Pharmaceutical Technology via Yahoo Finance· 3 days agoSince then, major strides have been made in the cell therapy space. The first chimeric antigen...
Astellas hitches a ride in Poseida's convertible for $50M cell therapy collaboration
FierceBiotech· 20 hours agoPoseida would also receive royalties on future sales. Poseida will combine its allogeneic CAR-T...
Do cutting-edge CAR-T-cell therapies cause cancer? What the data say
Nature· 3 days agoRegulators have identified around 30 cases of cancer linked to this blockbuster treatment. But is...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 hours agoPlanegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of